PERSONALIZING CANCER
TREATMENTS.
BUILT ON REAL HUMAN BIOLOGY.
We believe cancer care should be as precise and personal as possible. Solid IO’s tumor-on-chip platform is transforming oncology, delivering real-time, patient-specific insights that empower clinicians to make life-changing treatment decisions. With Solid IO, the next era of precision oncology and immunotherapy begins here.
OUR MISSION
Bridging science
and care
At Solid IO, we combine deep scientific expertise with real-world clinical impact. Our team is pioneering patient-specific organ-on-chip technology to transform cancer care. By bridging the gap between research and treatment, we turn biological complexity into clear, actionable insights. The result? Smarter decisions, more precise immunotherapies, and a future where personalized medicine isn’t just possible — it’s standard.
Watch how we’re tackling one of the biggest challenges in cancer care
Our platform
Replicating the tumor environment
Solid IO replicates a patient’s tumor microenvironment, generating real-time insights into how cancers respond to immuno-oncology treatments. By combining our technology with bioengineering and AI, we enable precise, informed treatment decisions - before and during therapy.
Tailored precision
Captures each patient’s unique biology, delivering high-accuracy predictions of treatment responses.
Scalable simplicity
Works across multiple cancer types and immuno-oncology therapies, making precision diagnostics accessible to clinicians and researchers worldwide.
Collaborative power
We connect researchers, clinicians, and pharmaceutical innovators to drive immunotherapy and precision oncology breakthroughs.
More precise cancer treatment
Deliver targeted, data-driven treatments from day one, reducing trial and error.
Faster drug development
Shorten preclinical and clinical trial timelines, accelerate approvals and patient access.
BENEFITS
Precision with
impact
Better patient outcomes
Tailor treatments to reduce side effects and improve quality of life.
Expanding global access
Make advanced cancer diagnostics scalable and accessible worldwide.
Our partners
PARTNER WITH US
To the leaders and pioneers in cancer care
You drive innovation in cancer care. We are here to support your work - helping you accelerate therapeutic breakthroughs, personalized care, and advance cancer diagnostics. Let’s connect and explore how we can expand IO access together.
TEAM
Meet the pioneers
We are a growing team of dedicated, multidisciplinary experts in oncology, bioengineering, AI, and commercialization, all united by the mission to end guesswork in cancer care.
We're looking for the next member of our leadership team to build what's next with us.
CAREERS
Join Us!
If you would like to be part of our growing team, connect with us to explore opportunities at Solid IO.
Latest posts
Solid IO joins the Bayer Co.Lab community
The Co.Lab Berlin membership gives us a new way to stay close to the pharmaceutical industry as we develop new approaches for personalized cancer care.
FAQs
Solid IO’s organ-on-chip platform replicates the patient’s tumor microenvironment, including immune interactions, to provide real-time insights into therapy responses. This technology enables more precise treatment selection, advances immunotherapy research, and supports early-stage clinical trials for new drug development.
By offering patient-specific, biology-driven insights, our platform helps oncologists and researchers make more informed decisions about treatment selection. This reduces trial-and-error, improves patient outcomes, and minimizes unnecessary side effects. Additionally, it accelerates immuno-oncology drug development by providing early biomarker validation and patient stratification insights within.
Our platform supports pharmaceutical companies, biotech firms, and cancer clinics involved in immunotherapy and precision oncology research. It helps optimize drug development pipelines, refine patient selection for clinical trials, and improve preclinical modeling for targeted therapies.
Currently, our platform is for research use only (RUO). We are actively collaborating with partners in pharma, biotech, and clinical research to refine and validate the technology. We welcome new partners to join us in shaping the future of precision oncology.
Our technology supports early patient stratification, biomarker validation, and real-time monitoring of treatment responses. These capabilities help shorten clinical trial timelines, reduce development costs, and improve the likelihood of success in bringing new immuno-oncology therapies to market.
Unlike traditional diagnostic models, our platform integrates patient-specific tumor environments with immune response modeling. This enables real-time insights into immunotherapies and combination treatments, providing a more accurate and scalable approach to personalized cancer care.
We collaborate with leading pharmaceutical companies, biotech firms, and cancer research centers to advance immuno-oncology treatments and precision oncology. Our partnerships focus on optimizing trial design, refining treatment selection, and accelerating access to next-generation therapies.
We are focused on expanding our global footprint, strengthening collaborations in the U.S. and European markets, and advancing our technology toward clinical applications. Our goal is to drive the adoption of organ-on-chip innovation in real-world oncology settings.
We are actively seeking partners - researchers, clinicians, and investors — who share our mission to end guesswork in cancer care. Get in touch through our Contact Us page to explore collaboration opportunities.
Shape the future of cancer care
Real progress happens through collaboration. We invite bold, forward-thinking partners- researchers, clinicians, and investors - to join us in making precision medicine truly impactful, and the new stanard in cancer care.